Sex differences in the prediction of neuroleptic response

  • M. V. Seeman


It is currently not possible to accurately predict neuroleptic response. It is not known which acutely psychotic patients will respond to drugs with relative speed and comprehensiveness, or at low, as compared to standard doses. It is not known which patients will remain relapse-free over a given time period on maintenance neuroleptic therapy. It is not known which patients will sustain full, as distinct from partial, remission in response to maintenance drug therapy. It is not known which patients, after a stable period, will be able to undergo dose reductions without a return of symptoms or of dysfunction (Gaebel et al. 1987).


Schizophrenic Patient Tardive Dyskinesia Neuroleptic Treatment Acute Dystonia BioI Psychiatry 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Addington J, Addington D (1993) Premorbid functioning, cognitive functioning, symptoms, and outcome in schizophrenia. J Psychiatr Neurosci 18:18–23.Google Scholar
  2. Angermeyer MC, Goldstein JM, Kühn L (1989) Gender differences in schizophrenia: rehospitalization and community survival. Psychol Med 19:365–382.PubMedCrossRefGoogle Scholar
  3. Awad AG (1992) Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Commun Psychiatry 43:262–265.Google Scholar
  4. Awad AG (1993) Subjective response to neuroleptics in schizophrenia. Schizophr Bull 19:609–618.PubMedGoogle Scholar
  5. Ayd FJ (1960) A survey of drug induced extrapyramidal reactions. JAMA 175:1054–1060.CrossRefGoogle Scholar
  6. Breier A, Schreiber JL, Dyer J, Pickar D (1991) NIMH longitudinal study of chronic schizophrenics. Arch Gen Psychiatry 48:239–246.PubMedCrossRefGoogle Scholar
  7. Chakos MH, Mayerhoff DI, Loebel AD, Alvir JMA, Lieberman JA (1992) Incidence and correlates of acute extrapyramidal symptoms in first episode schizophrenia. Psychopharmacol Bull 28:81–86.PubMedGoogle Scholar
  8. Chouinard G, Annable L (1982) Pimozide in the treatment of newly admitted schizophrenic patients. Psychopharmacology 76:13–19.PubMedCrossRefGoogle Scholar
  9. Chouinard G, Annable L (1986) A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic in schizophrenic patients with acute exacerbation. J Clin Psychopharmacol 6:21–26.PubMedCrossRefGoogle Scholar
  10. Ciompi L (1980) The natural history of schizophrenia in the long-term. Br J Psychiatry 136:413–420.PubMedCrossRefGoogle Scholar
  11. Corrigan PW, Liberman RP, Engel JD (1990) From noncompliance to collaboration in the treatment of schizophrenia. Hosp Commun Psychiatry 41:1203–1211.Google Scholar
  12. Dale R, Langdon M, Seeman MV (1994) Reducing the dose of depot neuroleptic in stable schizophrenia. J Psychiatr Neurosci 19 (in press).Google Scholar
  13. Datz FL, Christian PS, Moore J (1987) Gender-related differences in gastric emptying. J Nucl Med 28:1204–1207.PubMedGoogle Scholar
  14. Ereshefsky I, Saklad SR, Watanabe MD, Davis CM, Jann MW (1991) Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J Clin Psychopharmacol 11:296–301.PubMedCrossRefGoogle Scholar
  15. Farde L, Wiesel FA, Nordstrom A, Sedvall G (1989) D1-and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99:528–531.CrossRefGoogle Scholar
  16. Fenton WF, McGlashan TH (1987) Sustained remission in drug-free schizophrenic patients. Am J Psychiatry 144:1306–1309.PubMedGoogle Scholar
  17. Frank AF, Gunderson JG (1990) The role of the therapeutic alliance in the treatment of schizophrenia: relationship to course and outcome. Arch Gen Psychiatry 47:228–238.PubMedCrossRefGoogle Scholar
  18. Gaebel W, Pietzcker A (1987) Prospective study of the course of illness in schizophrenia, part II. Prediction of outcome. Schizophr Bull 13:299–306.PubMedGoogle Scholar
  19. Glick ID, Spencer JH, Clarkin JF, Haas GL, Lewis AB, Peyser J, DeMane N, Good-Ellis M, Harris E, Lestell V (1990) A randomized trial of inpatient family intervention. IV. Follow-up results for subjects with schizophrenia. Schizophr Res 3:187–200.PubMedCrossRefGoogle Scholar
  20. Goldberg SC, Schooler NR, Davidson EM, Kayce MM (1966) Sex and race differences in response to drug treatment among schizophrenics. Psychopharmacologia (Berlin) 9:31–47.CrossRefGoogle Scholar
  21. Goldstein JM (1988) Gender differences in the course of schizophrenia. Am J Psychiatry 145:684–689.PubMedGoogle Scholar
  22. Gur RC, Gur RE, Obrist WD, Hungerbuhler JP, Younkin D, Rosen AD, Skolnik BE, Reivich M (1982) Sex and handedness differences in cerebral blood flow during rest and cognitive activity. Science 217:659–661.PubMedCrossRefGoogle Scholar
  23. Häfner H, Behrens S, De Vry J, Gattaz WF (1991) An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia. Psychiatry Res 38:125–134.PubMedCrossRefGoogle Scholar
  24. Hallonquist J, Seeman MV, Lang M, Rector N (1993) Variation in symptom severity over the menstrual cycle of schizophrenics. Biol Psychiatry 33:207–209.PubMedCrossRefGoogle Scholar
  25. Harding CM, Brooks GW, Ashigaga T, Strauss JS, Breier A (1987) The Vermont longitudinal study of persons with severe mental illness. II. Longterm outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry 144:727–735.PubMedGoogle Scholar
  26. Haring C, Meise U, Humpel C, Saria A, Fleischhacker WW, Hinterhumber H (1989) Doserelated plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology 99:S38–S40.PubMedCrossRefGoogle Scholar
  27. Hogan TP, Awad AG, Eastwood MR (1985) Early subjective response and prediction of outcome in neuroleptic drug therapy in schizophrenia. Can J Psychiatry 30:246–248.PubMedGoogle Scholar
  28. Holding TA, Urbane S, Kay DWK (1983) Social outcome after first admission for schizophrenia in Tasmania: a study of matched pairs. Soc Psychiatry 18:145–152.PubMedCrossRefGoogle Scholar
  29. Hruska RE (1986) Elevation of striatal dopamine receptors by estrogen. Dose and time studies. J Neurochem 47:1908–1915.PubMedCrossRefGoogle Scholar
  30. Inoue K, Nakajima T, Kato N (1986) A longitudinal study of schizophrenia in adolescence I. The one-to three-year outcome. Jpn J Psychiatr Neurol 40:143–151.Google Scholar
  31. Jonsson H, Nyman AK (1991) Predicting long-term outcome in schizophrenia. Acta Psychiatr Scand 83:342–346.PubMedCrossRefGoogle Scholar
  32. Kane JH, Marder SR (1993) Psychopharmacologic treatment of schizophrenia. Schizophr Bull 19:287–302.PubMedGoogle Scholar
  33. Keefe RSE, Mohs RC, Losonczy MF, Davidson M, Silverman JM, Horvath B, Davis KL (1989) Premorbid socio-sexual functioning and longterm outcome in schizophrenia. Am J Psychiatry 146:206–211.PubMedGoogle Scholar
  34. Keepers GA, Clappison VJ, Casey DE (1983) Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 40:1113–1117.PubMedCrossRefGoogle Scholar
  35. Kolakowska T, Williams AO, Ardern A, Reveley MA, Jambor K, Gelder MG, Mandelbrote BM (1985) Schizophrenia with good and poor outcome 1. Early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry 146:229–246.PubMedCrossRefGoogle Scholar
  36. Leff J, Sartorius N, Hablensky A, Korten A, Ernberg G (1992) The International Pilot Study of Schizophrenia: five-year follow-up findings. Psychol Med 22:131–145.PubMedCrossRefGoogle Scholar
  37. Lewis S (1992) Sex and schizophrenia. Vive la différence. Br J Psychiatry 161:445–450.PubMedCrossRefGoogle Scholar
  38. Lloyd D, Simpson JC, Tsuang MT (1985) Are there sex differences in the long-term outcome of schizophrenia? J Nerv Ment Dis 173:643–649.CrossRefGoogle Scholar
  39. Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski ST (1992) Duration of psychosis and outcome in first episode schizophrenia. Am J Psychiatry 149:1183–1188.PubMedGoogle Scholar
  40. McCreadie RG, Robertson LJ, Wiles DH (1992) The Nithsdale schizophrenia surveys. IX. Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels. Br J Psychiatry 161:793–799.CrossRefGoogle Scholar
  41. McEvoy JP, Hogarty G, Steingard S (1991) Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48:739–745.PubMedCrossRefGoogle Scholar
  42. McGlashan TH (1986a) The prediction of outcome in chronic schizophrenia. Arch Gen Psychiatry 43:167–176.PubMedCrossRefGoogle Scholar
  43. McGlashan TH (1986b) Predictors of shorter-, medium-, and longer-term outcome in schizophrenia. Am J Psychiatry 143:50–55.PubMedGoogle Scholar
  44. McGlashan TH (1988) A selective review of recent North American longterm follow-up studies of schizophrenia. Schizophr Bull 14:515–542.PubMedGoogle Scholar
  45. Morgenstern H, Glazer WM (1993) Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medication. Arch Gen Psychiatry 50:723–733.PubMedCrossRefGoogle Scholar
  46. Nedopil N, Pflieger R, Rüther E (1983) The prediction of acute response, remission, and general outcome of neuroleptic treatment in acute schizophrenic patients. Pharmacopsychiatry 16:201–205.CrossRefGoogle Scholar
  47. Niznik H, Van Tol HHM (1992) Dopamine receptor genes: new tools for molecular psychiatry. J Psychiatr Neurosci 17:158–180.Google Scholar
  48. Nyman AK, Jonsson H (1983) Differential evaluation of outcome in schizophrenia. Acta Psychiatr Scand 68:458–475.PubMedCrossRefGoogle Scholar
  49. Opjordsmoen S (1991) Long-term clinical outcome of schizophrenia with special reference to gender differences. Acta Psychiatr Scand 83:307–313.PubMedCrossRefGoogle Scholar
  50. Pakaslahti A (1992) Prediction of working disability in schizophrenia: a 5-year prospective study of a representative cohort of first-admissons. Publications of the Social Insurance Institution, Finland, ML #119, 1–102.Google Scholar
  51. Pyke J, Seeman MV (1981) Neuroleptic-free intervals in the treatment of schizophrenia. Am J Psychiatry 138:1620–1621.PubMedGoogle Scholar
  52. Salokangas RKR, Stengard E (1990) Gender and short-term outcome in schizophrenia. Schizophr Res 3:333–345.PubMedCrossRefGoogle Scholar
  53. Seeman MV (1983a) Schizophrenic men and women require different treatment programs. J Psychiatr Treatment Evaluation 5:143–148.Google Scholar
  54. Seeman MV (1983b) Interaction of sex, age, and neuroleptic dose. Compr Psychiatry 24:125–128.PubMedCrossRefGoogle Scholar
  55. Seeman MV (1985) Clinical and demographic correlates of neuroleptic response. Can J Psychiatry 30:243–245.PubMedGoogle Scholar
  56. Seeman MV (1986) Current outcome in schizophrenia: women vs men. Acta Psychiatr Scand 73:609–617.PubMedCrossRefGoogle Scholar
  57. Seeman MV (1989) Prescribing neuroleptics for men and women. J Soc Pharmacol 3:219–236.Google Scholar
  58. Seeman MV (1994) The schizophrenic mother. In: Gopfert M, Webster J, Seeman MV (eds) Disturbed and mentally ill parents and their children. Cambridge University Press, Cambridge (in press).Google Scholar
  59. Seeman MV, Lang (1990) The role of estrogens in schizophrenia gender differences. Schizophr Bull 16:185–194.PubMedGoogle Scholar
  60. Straube ER, Wagner W, Foerster K, Heimann H (1989) Findings significant with respect to short-and medium-term outcome in schizophrenia — preliminary report. Prog Neuro-psychopharmacol Biol Psychiatry 13:185–197.CrossRefGoogle Scholar
  61. Swett C (1975) Drug-induced dystonia. Am J Psychiatry 132:532–534.PubMedGoogle Scholar
  62. Thara R, Rajkumar A (1992) Gender differences in schizophrenia: results of a follow-up study in India. Schizophr Res 7:65–70.PubMedCrossRefGoogle Scholar
  63. Toran-Allerand CD (1990) Interactions of estrogens with growth factors in the developing central nervous system. In: Hochberg RB, Naftolin F (eds) The new biology of steroid hormones. Raven Press, New York, pp 311–323.Google Scholar
  64. Toran-Allerand CD (1991) Organotypic culture of the developing cerebral cortes and hypothalamus: relevance to sexual differentiation. Psychoneuroendocrinology 16:7–24.PubMedCrossRefGoogle Scholar
  65. Van Putten T, May PRA (1978) Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Arch Gen Psychiatry 35:477–480.PubMedCrossRefGoogle Scholar
  66. Watt DC, Katz K, Shepherd M (1983) The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment. Psychol Med 13:663–670.PubMedCrossRefGoogle Scholar
  67. Westermeyer JF, Harrow M (1984) Prognosis and outcome using broad (DSM-II) and narrow (DSM-III) concepts of schizophrenia. Schizophr Bull 10:624–637.PubMedGoogle Scholar
  68. Wode-Helgodt B, Borg S, Fryrö B, Sedvall G (1978) Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatr Scand 58:149–173.PubMedCrossRefGoogle Scholar
  69. Yassa R, Jeste DV (1992) Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 18:701–715.PubMedGoogle Scholar
  70. Yonkers KA, Kando JC, Cole JO, Blumenthal S (1992) Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 149:587–595.PubMedGoogle Scholar
  71. Young MA, Meltzer HY (1980) The relationship of demographic, clinical, and outcome variables to neuroleptic treatment requirements. Schizophr Bull 6:88–101.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 1994

Authors and Affiliations

  • M. V. Seeman
    • 1
  1. 1.Department of Psychiatry, Clarke Institute of PsychiatryUniversity of TorontoTorontoCanada

Personalised recommendations